Truvada Tablet

Adult dose

Recommended dosage for the treatment of HIV-1 infection: The recommended dosage of this drug in adults is 1 tablet once daily (containing emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg), taken orally with or without food. Recommended dosage to reduce the risk of HIV-1 infection before exposure in HIV-1-uninfected individuals at high risk: The dosage of this drug for HIV-1-uninfected adults is 1 tablet once daily (containing emtricitabine 200mg and tenofovir disoproxil fumarate 300mg), taken orally with or without food. Adult patients being treated for HIV-1 infection: Creatinine clearance ≥50 mL/min, every 24 hours; creatinine clearance 30-49 mL/min, every 48 hours; creatinine clearance <30 (including patients requiring hemodialysis), do not administer this drug. Reduction of the risk of HIV-1 infection before exposure in HIV-1-uninfected individuals at high risk: This drug should not be used in patients with an estimated creatinine clearance of less than 60 mL/min.

Child dose

Adolescents aged 12 years or older and weighing 35 kg or more: 1 tablet once daily (containing emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg), taken orally with or without food.

This medication can cause serious issues with the liver, therefore patients with liver disease or suspected liver dysfunction should take special caution. This medication is not approved for the treatment of chronic Hepatitis B, and there is a risk of exacerbation of hepatitis if this medication is discontinued in patients co-infected with Hepatitis B and HIV-1. This medication should only be used to reduce the risk of HIV-1 infection, and high-risk individuals must strictly adhere to safe sex practices, such as using condoms. This medication should not be administered to patients with certain genetic disorders or who have hypersensitivity to this drug. Patients with impaired kidney function should have their kidney function monitored periodically while taking this medication, and adjust dosing intervals as necessary. This medication should not be used in conjunction with certain other antiviral agents, as combining them may increase the risk of adverse drug interactions. During treatment, there may be a decrease in bone mineral density, and patients at risk for osteoporosis should consider bone density testing and may benefit from calcium and vitamin D supplementation. This medication should only be used during pregnancy when absolutely necessary, and nursing mothers should avoid breastfeeding while taking this medication. This medication should only be administered to adolescents above a certain weight threshold, and caution should be exercised when prescribing it to children or the elderly. During treatment, regular tests such as liver function, kidney function, and blood tests should be conducted to monitor for adverse reactions. In case of overdose, the patient should be carefully monitored, and appropriate treatment should be provided as necessary. This medication should be stored away from direct sunlight and kept at room temperature, securely locked away from children.

Severe liver enlargement accompanied by steatosis, liver dysfunction, liver failure, diarrhea, vomiting, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, rash, skin depigmentation, anxiety, arthralgia, increased coughing, indigestion, fever, myalgia, pain, abdominal pain, low back pain, paresthesia, peripheral neuropathy, pneumonia, rhinitis, anemia, pigmentation, pharyngitis, urethritis, urinary tract infection, syphilis, secondary syphilis, anal genital warts, low back pain, headache, depression, anxiety, genital ulcers, weight loss, osteoporosis, eczema, allergic reaction, angioedema, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, increased amylase, abdominal pain, fatty liver disease, hepatitis, increased liver enzymes, rash, rhabdomyolysis, osteomalacia, muscle weakness, myopathy, acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal tubular acidosis, interstitial nephritis, nephrogenic diabetes insipidus, increased creatinine, proteinuria, polyuria, asthenia

This medication should be stored in a tightly sealed container to protect it from air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. Therefore, it should be kept away from direct sunlight and not placed in excessively hot or cold locations.

Appearance

A blue, rectangular film-coated tablet with “GILEAD” embossed on one side and “701” on the other side.

Package unit

30 tablets/bottle